Charles Schwab’s Elicio Therapeutics ELTX Stock Holding History

Charles Schwab’s Portfolio ELTX Stock Details ELTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$124K	Buy	+31,706	New	+$318K	﹤0.01%	3403
2022 Q2	–	Sell	-4,575	Closed	-$97K	–	3566
2022 Q1	$97K	Hold	4,575	–	–	﹤0.01%	3418
2021 Q4	$133K	Hold	4,575	–	–	﹤0.01%	3412
2021 Q3	$448K	Buy	4,575 +1,254	+38%	+$135K	﹤0.01%	3177
2021 Q2	$433K	Sell	3,321 -161	-5%	-$23.2K	﹤0.01%	3197
2021 Q1	$630K	Buy	+3,482	New	+$672K	﹤0.01%	3009

Other funds holding ELTX

KCM

Knoll Capital Management Miami, Florida $214M AUM 62.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Charles Schwab's ELTX Position: Q2 2026 in Review

Charles Schwab opened a new position in Elicio Therapeutics (ELTX) in Q2 2026: 31,706 shares worth $124K. The stake represents ﹤0.01% of the portfolio and ranks #3403 among its holdings. This is a return to the name: Charles Schwab previously reported a position in ELTX as recently as Q1 2022.

Charles Schwab first reported a position in ELTX in Q1 2021 and has held it in 6 quarters since. The position peaked at $630K in Q1 2021. 48 funds tracked by Wall St. Rank hold ELTX as of Q2 2026.

Charles Schwab held 31,706 shares of Elicio Therapeutics worth $124K as of Q2 2026.
Elicio Therapeutics was a new Charles Schwab position in Q2 2026.
Elicio Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #3403 holding.
Charles Schwab first reported a position in Elicio Therapeutics in Q1 2021 and has held it in 6 quarters since.
Charles Schwab's Elicio Therapeutics position peaked at $630K in Q1 2021.
48 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.